Classifications: proton pump inhibitor; Therapeutic: antiulcer; proton pump inhibitor
Pregnancy Category: B
20 mg tablets
Gastric proton pump inhibitor that specifically suppresses gastric acid secretion by inhibiting the H+, K+-ATPase enzyme system [the acid (proton H+) pump] in the parietal cells of the stomach. Produces an antisecretory effect on the hydrogen ion (H+) in the parietal cells.
Effectiveness indicated by a negative urea breath test for H. pylori with preexisting gastric ulcer; also by elimination of S&S of GERD or peptic ulcers.
Healing and maintenance of healing of erosive or ulcerative gastroesophageal reflux disease (GERD); healing of duodenal ulcers;
treatment of hypersecretory conditions.
Hypersensitivity to rabeprazole, lansoprazole, or omeprazole or proton pump inhibitors (PPIs); lactation.
Pregnancy (category B); severe hepatic impairment; mild to moderate hepatic disease; Japanese. Safety and efficacy in children
<18 y are not established.
Route & Dosage
|Healing of Erosive GERD
Adult: PO 20 mg q.d. x 48 wk, may continue up to 16 wk if needed
Maintenance Therapy for GERD
Adult: PO 20 mg q.d.
Healing Duodenal Ulcer
Adult: PO 20 mg q.d. x 4 wk
Adult: PO 60 mg q.d. in 12 divided doses (max: 100 mg q.d. or 60 mg b.i.d.)
- Adjust dose as needed with preexisting liver disease.
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)Body as a Whole:
(Rare) Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.
May decrease absorption of ketoconazole;
may increase digoxin
levels. Herbal: Ginkgo
may decrease plasma levels.
52% bioavailability. Distribution:
96% protein bound. Metabolism:
In liver by (CYP3A4, 2C19). Elimination:
Primarily in urine. Half-Life:
Assessment & Drug Effects
- Lab tests: Routine serum chemistry; serum gastrin in long-term therapy.
- Coadministered drugs: Monitor for changes in digoxin blood level.
Patient & Family Education
- Report diarrhea, skin rash, other bothersome adverse effects to physician.